多种可溶性CD146变体参与系统性硬化症:一种新型促纤维化因子的鉴定
该研究通过体外实验(RNA测序和抗体芯片)及博来霉素诱导的系统性硬化症(SSc)和下肢缺血动物模型,发现可溶性CD146(sCD146)存在脱落型和两种新的剪接变体(I5-13-sCD146和I10-sCD146)。SSc患者血清中I5-13-sCD146显著升高(P < 0.001;n = 117),尤其在肺纤维化患者中(P < 0.01;n = 112),而I10-sCD146降低(P < 0.05;n = 117)。脱落型sCD146和I10-sCD146分别通过黏着斑激酶和蛋白激酶Cε信号通路发挥促血管生成活性,I5-13-sCD146则通过Wnt-1/β-catenin/WISP-1通路发挥促纤维化作用。作者认为sCD146变体,尤其是新型I5-13-sCD146剪接变体,可能成为SSc诊断和治疗的生物标志物和/或分子靶点。
要点
- SSc患者血清I5-13-sCD146显著升高(P < 0.001;n = 117),肺纤维化患者中亦升高(P < 0.01;n = 112)。
- I10-sCD146在SSc患者血清中降低(P < 0.05;n = 117)。
- I5-13-sCD146通过Wnt-1/β-catenin/WISP-1通路发挥促纤维化作用。
核心结论
- sCD146变体,尤其是新型I5-13-sCD146剪接变体,可能成为SSc及其他血管生成或纤维化相关疾病的诊断和治疗生物标志物和/或分子靶点。
研究设计与样本
- 体外实验包括RNA测序和抗体芯片,体内实验使用博来霉素诱导的SSc和下肢缺血动物模型。
主要发现
- 发现sCD146存在脱落型和两种新的剪接变体(I5-13-sCD146和I10-sCD146)。
- 脱落型sCD146由CD146长膜异构体经ADAM-10金属蛋白酶切割、短膜异构体经TACE金属蛋白酶切割生成。
- SSc患者血清I5-13-sCD146显著升高(P < 0.001;n = 117),尤其肺纤维化患者中升高(P < 0.01;n = 112)。
- SSc患者血清I10-sCD146降低(P < 0.05;n = 117)。
- 脱落型sCD146通过黏着斑激酶通路、I10-sCD146通过蛋白激酶Cε通路发挥促血管生成活性,I5-13-sCD146通过Wnt-1/β-catenin/WISP-1通路发挥促纤维化作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Systemic sclerosis (SSc) is an autoimmune disorder characterized by excessive fibrosis, immune dysfunction, and vascular damage, in which the expression of many growth factors is deregulated. CD146 was recently described as a major actor in SSc. Since CD146 also exists as a circulating soluble form (sCD146) that acts as a growth factor in numerous angiogenic- and inflammation-related pathologies, we sought to identify the mechanisms underlying the generation of sCD146 and to characterize the regulation and functions of the different variants identified in SSc. METHODS: We performed in vitro experiments, including RNA-Seq and antibody arrays, and in vivo experiments using animal models of bleomycin-induced SSc and hind limb ischemia. RESULTS: Multiple forms of sCD146, generated by both shedding and alternative splicing of the primary transcript, were discovered. The shed form of sCD146 was generated from the cleavage of both long and short membrane isoforms of CD146 through ADAM-10 and TACE metalloproteinases, respectively. In addition, 2 novel sCD146 splice variants, I5-13-sCD146 and I10-sCD146, were identified. Of interest, I5-13-sCD146 was significantly increased in the sera of SSc patients (P < 0.001; n = 117), in particular in patients with pulmonary fibrosis (P < 0.01; n = 112), whereas I10-sCD146 was decreased (P < 0.05; n = 117). Further experiments revealed that shed sCD146 and I10-sCD146 displayed proangiogenic activity through the focal adhesion kinase and protein kinase Cε signaling pathways, respectively, whereas I5-13-sCD146 displayed profibrotic effects through the Wnt-1/β-catenin/WISP-1 pathway. CONCLUSION: Variants of sCD146, and in particular the novel I5-13-sCD146 splice variant, could constitute novel biomarkers and/or molecular targets for the diagnosis and treatment of SSc and other angiogenesis- or fibrosis-related disorders.
引用
- Nollet M, Bachelier R, Joshkon A, et al. Involvement of Multiple Variants of Soluble CD146 in Systemic Sclerosis: Identification of a Novel Profibrotic Factor. Arthritis Rheumatol. 2022. PMID: 35001552. doi:10.1002/art.42063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。